X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs NATCO PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS NATCO PHARMA NOVARTIS/
NATCO PHARMA
 
P/E (TTM) x 424.9 13.0 3,259.0% View Chart
P/BV x 30.0 2.7 1,101.2% View Chart
Dividend Yield % 1.5 1.6 93.2%  

Financials

 NOVARTIS   NATCO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
NATCO PHARMA
Mar-18
NOVARTIS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs7581,080 70.2%   
Low Rs579671 86.3%   
Sales per share (Unadj.) Rs228.4592.1 38.6%  
Earnings per share (Unadj.) Rs31.7188.4 16.8%  
Cash flow per share (Unadj.) Rs32.8206.3 15.9%  
Dividends per share (Unadj.) Rs10.008.25 121.2%  
Dividend yield (eoy) %1.50.9 158.8%  
Book value per share (Unadj.) Rs297.1833.6 35.6%  
Shares outstanding (eoy) m24.6936.90 66.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.91.5 197.9%   
Avg P/E ratio x21.14.6 453.2%  
P/CF ratio (eoy) x20.44.2 480.8%  
Price / Book Value ratio x2.21.1 214.2%  
Dividend payout %31.54.4 719.5%   
Avg Mkt Cap Rs m16,50532,311 51.1%   
No. of employees `0000.74.8 13.8%   
Total wages/salary Rs m1,4453,256 44.4%   
Avg. sales/employee Rs Th8,441.34,522.5 186.7%   
Avg. wages/employee Rs Th2,163.6674.0 321.0%   
Avg. net profit/employee Rs Th1,173.11,439.0 81.5%   
INCOME DATA
Net Sales Rs m5,63921,848 25.8%  
Other income Rs m1,718404 425.3%   
Total revenues Rs m7,35722,252 33.1%   
Gross profit Rs m-639,284 -0.7%  
Depreciation Rs m25662 3.8%   
Interest Rs m55154 35.9%   
Profit before tax Rs m1,5758,872 17.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7921,920 41.2%   
Profit after tax Rs m7846,952 11.3%  
Gross profit margin %-1.142.5 -2.6%  
Effective tax rate %50.321.6 232.2%   
Net profit margin %13.931.8 43.7%  
BALANCE SHEET DATA
Current assets Rs m9,52221,307 44.7%   
Current liabilities Rs m3,2965,920 55.7%   
Net working cap to sales %110.470.4 156.8%  
Current ratio x2.93.6 80.3%  
Inventory Days Days3773 50.0%  
Debtors Days Days28107 26.7%  
Net fixed assets Rs m4614,986 0.3%   
Share capital Rs m123369 33.4%   
"Free" reserves Rs m7,21330,353 23.8%   
Net worth Rs m7,33630,760 23.9%   
Long term debt Rs m00-   
Total assets Rs m11,10537,151 29.9%  
Interest coverage x29.558.6 50.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 86.3%   
Return on assets %7.619.1 39.5%  
Return on equity %10.722.6 47.3%  
Return on capital %22.229.3 75.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6110,322 0.6%   
Fx outflow Rs m3,6302,978 121.9%   
Net fx Rs m-3,5707,343 -48.6%   
CASH FLOW
From Operations Rs m1,6104,636 34.7%  
From Investments Rs m687-11,155 -6.2%  
From Financial Activity Rs m-2,6776,509 -41.1%  
Net Cashflow Rs m-380-18 2,108.9%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 2.0 7.8 25.5%  
FIIs % 1.6 16.6 9.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.0 82.7%  
Shareholders   41,647 25,395 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS